Author: Rachelle Ramirez

Platform-Disease Management

COVID-19 in Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease Patients in North America

Background: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) raised...

Read More

Platform-Psychosocial

Cogeval in the Real World: Feasibility, Implementation, and Practical Implications

Background: Cognitive dysfunction in multiple sclerosis (MS) patients is common, and routine/efficient screening for cognitive dysfunction...

Read More

Platform-Psychosocial

Association between Cognition and Social Role Participation Among Patients with Multiple Sclerosis

Background: Multiple sclerosis (MS), a relapsing and progressive demyelinating disease of the central nervous system, results in impaired...

Read More

Platform-Disease Modifying Therapies

COVID-19 Vaccine Response in People with MS Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab or Interferon Therapy

Background: COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into the...

Read More

Platform-Disease Management

Optical Coherence Tomography As a Biomarker for Multiple Sclerosis Studies

Background: Optic Neuritis occurs in about 20% of MS patients as the initial symptom. Objectives: To assess the clinical utility of optical...

Read More

Platform-Neuroimaging

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Background: Standardized magnetic resonance imaging (MRI) guidelines published in 2015 by the MAGNIMS group and in 2016 by the CMSC are...

Read More

Platform-Psychosocial

Health-Related Quality of Life across the Lifespan in Persons with Multiple Sclerosis and Healthy Controls

Background: Health-related quality of life (HRQOL) is reduced in persons with multiple sclerosis (MS) compared with the general population,...

Read More